Skip to main content
. 2022 Apr 1;13:838171. doi: 10.3389/fphar.2022.838171

FIGURE 3.

FIGURE 3

PTPRO is downregulated in lapatinib-resistant ERBB2-positive breast cancer cells. (A) The mRNA level of PTPRO in the lapatinib resistant ERBB2-positive breast cancer cells, SKBR3-lapR and BT474-lapR, compared with their parental cells, SKBR3-P and BT474-P. The dataset GSE38376 and GSE16179 were get from GEO (https://www.ncbi.nlm.nih.gov/geo/). (B) Inhibition ratio analysis of SKBR3-lapR and SKBR3-P (upper panel), BT474-lapR and BT474-P (bottom panel) was evaluated by MTT assay after treatment with lapatinib. (C) Colony formation abilities of SKBR3-lapR and SKBR3-P (left panel), BT474-lapR and BT474-P (right panel) were evaluated after treatment with lapatinib, and the number of colonies was counted (bottom panel). (D) The PTPRO protein expression derived from lapatinib resistant ERBB2-positive cells and their parental cells were assessed by western blot analysis. Data were shown as the means of three independent experiments or representative data. Error bars indicate SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by Student’s t-test or one-way ANOVA with post hoc intergroup comparisons, where appropriate.